Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3377299 | 1.00 | CYP1A2 (0.50) | CYP1A2CYP2C19CYP3A4CYP2C9TRPA1 | |
| SCHEMBL4388708 | 0.81 | CYP1A2 (0.51) | CYP1A2CYP2C19CYP3A4CYP2C9TRPA1 | |
| SCHEMBL20801864 | 0.81 | TRPA1 (0.46) | CYP1A2CYP2C19CYP3A4CYP2C9TRPA1 | |
| SCHEMBL7947844 | 0.81 | ALDH1A1 (0.44) | CYP3A4CYP2C9ALDH1A1SMN1; SMN2TBXAS1 | |
| SCHEMBL11829415 | 0.81 | NFKB1 (0.46) | CYP3A4CYP2C9TRPA1ALDH1A1SMN1; SMN2 | |
| SCHEMBL24587500 | 0.81 | ALDH1A1 (0.44) | CYP3A4CYP2C9ALDH1A1SMN1; SMN2TBXAS1 | |
| SCHEMBL2555914 | 0.81 | SMN1; SMN2 (0.41) | CYP3A4CYP2C9ALDH1A1SMN1; SMN2NFE2L2 | |
| SCHEMBL2555913 | 0.81 | SMN1; SMN2 (0.41) | CYP3A4CYP2C9ALDH1A1SMN1; SMN2NFE2L2 | |
| SCHEMBL31118194 | 0.80 | POLB (0.45) | ALDH1A1RAB9ANFE2L2PPARGPKM | |
| SCHEMBL12498711 | 0.79 | HSD11B1 (0.44) | CYP3A4CYP2C9TBXAS1EPHX2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1796665-B1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK SHARP & DOHME (US) | 2010-11-17 | — | — | EP | disclosed |
| US-7629372-B2 | Compounds for the treatment of dyslipidemia and other lipid disorders | MERCK & CO., INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-7524882-B2 | PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | MERCK & CO., INC. (US) | 2009-04-28 | — | — | US | disclosed |
| EP-1539136-B1 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK & CO INC (US) | 2008-07-09 | — | — | EP | disclosed |
| US-20080039514-A1 | Compounds for the Treatment of Dyslipidemia and Other Lipid Disorders | MERCK & CO., INC. (US) | 2008-02-14 | — | — | US | disclosed |
| EP-1539136-A4 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK & CO INC (US) | 2006-10-18 | — | — | EP | disclosed |
| US-20050228044-A1 | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | MERCK SHARP & DOHME CORP. | 2005-10-13 | — | — | US | disclosed |
| EP-1539136-A2 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | Merck & Co., Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004010936-A2 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK & CO., INC. (US) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039514-A1 | Compounds for the Treatment of Dyslipidemia and Other Lipid Disorders | LIPA, APOB, LCAT | CYP1A2 731/4885CYP2C19 976/4885CYP3A4 818/4885 |
| US-20050228044-A1 | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | PPARD, PPARA, PPARG | CYP1A2 445/4885CYP2C19 680/4885CYP3A4 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.